Cargando…

Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells

BACKGROUND: Myeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer response to immunotherapy, and poorer survival. Optimal measurement of MDSC leve...

Descripción completa

Detalles Bibliográficos
Autores principales: Apodaca, Minjun C., Wright, Amy E., Riggins, Angela M., Harris, William P., Yeung, Raymond S., Yu, Lei, Morishima, Chihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714080/
https://www.ncbi.nlm.nih.gov/pubmed/31462270
http://dx.doi.org/10.1186/s40425-019-0674-1
_version_ 1783446984138424320
author Apodaca, Minjun C.
Wright, Amy E.
Riggins, Angela M.
Harris, William P.
Yeung, Raymond S.
Yu, Lei
Morishima, Chihiro
author_facet Apodaca, Minjun C.
Wright, Amy E.
Riggins, Angela M.
Harris, William P.
Yeung, Raymond S.
Yu, Lei
Morishima, Chihiro
author_sort Apodaca, Minjun C.
collection PubMed
description BACKGROUND: Myeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer response to immunotherapy, and poorer survival. Optimal measurement of MDSC levels could provide clinicians with a useful prognostic and/or management tool. METHODS: A whole blood (WB) nine color, 11 parameter flow cytometric assay was designed, utilizing fluorescently-labeled antibodies against CD45, CD3, CD19, CD20, CD56, CD16, HLA-DR, CD33, CD11b, CD14 and CD15, and BD Trucount beads for quantitation. Total MDSC were defined as CD45 + CD3(−)CD19(−)CD20(−)CD56(−)CD16(−)HLA-DR(−)CD33 + CD11b + cells, while the monocytic (M-MDSC) and polymorphonuclear subsets were defined as CD14+ or CD15+, respectively. RESULTS: A novel gating strategy was devised to eliminate granulocytes and improve consistency in gating. Several pre-analytical variables were found to significantly affect MDSC quantitation, including collection tube type and time elapsed between blood collection and testing. Total and M-MDSC levels were a mean of 63% and 73% greater, respectively, with K(2)EDTA compared to Na(+)heparin collection tubes (N = 5). In addition, time elapsed at room temperature prior to cell labeling affected MDSC quantitation; by 24 h after blood collection, total and M-MDSC levels were a mean of 26% and 57% lower compared to testing as soon as possible after collection (N = 6). Refrigeration of samples at 4 °C ameliorated time-dependent effects at both 4 and 8 h, but not 24 h after blood collection. To establish normal ranges for this assay, MDSC levels were quantified in 67 healthy subjects (30 male, 37 female) ages 20–93. No significant differences in total or M-MDSC levels were detected for ages ≤60 compared to > 60 (p = 0.5 and p = 0.8, respectively). Finally, assay results demonstrated significantly higher MDSC levels among patients with hepatocellular carcinoma (N = 55) compared to age-matched healthy controls (N = 27) for total and M-MDSC (p = 0.006 and 0.004, respectively). CONCLUSIONS: MDSC are a heterogenous group of cells, and their quantitation in WB can be affected by a number of pre-analytical variables. Consideration of these factors, and measurement using a material type that has not been manipulated, such as whole blood, is likely to yield the most accurate results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0674-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6714080
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67140802019-09-04 Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells Apodaca, Minjun C. Wright, Amy E. Riggins, Angela M. Harris, William P. Yeung, Raymond S. Yu, Lei Morishima, Chihiro J Immunother Cancer Research Article BACKGROUND: Myeloid-derived suppressor cells (MDSC) have been found to play an important role in limiting immune responses in cancer. Higher circulating MDSC levels have been associated with greater tumor burden, poorer response to immunotherapy, and poorer survival. Optimal measurement of MDSC levels could provide clinicians with a useful prognostic and/or management tool. METHODS: A whole blood (WB) nine color, 11 parameter flow cytometric assay was designed, utilizing fluorescently-labeled antibodies against CD45, CD3, CD19, CD20, CD56, CD16, HLA-DR, CD33, CD11b, CD14 and CD15, and BD Trucount beads for quantitation. Total MDSC were defined as CD45 + CD3(−)CD19(−)CD20(−)CD56(−)CD16(−)HLA-DR(−)CD33 + CD11b + cells, while the monocytic (M-MDSC) and polymorphonuclear subsets were defined as CD14+ or CD15+, respectively. RESULTS: A novel gating strategy was devised to eliminate granulocytes and improve consistency in gating. Several pre-analytical variables were found to significantly affect MDSC quantitation, including collection tube type and time elapsed between blood collection and testing. Total and M-MDSC levels were a mean of 63% and 73% greater, respectively, with K(2)EDTA compared to Na(+)heparin collection tubes (N = 5). In addition, time elapsed at room temperature prior to cell labeling affected MDSC quantitation; by 24 h after blood collection, total and M-MDSC levels were a mean of 26% and 57% lower compared to testing as soon as possible after collection (N = 6). Refrigeration of samples at 4 °C ameliorated time-dependent effects at both 4 and 8 h, but not 24 h after blood collection. To establish normal ranges for this assay, MDSC levels were quantified in 67 healthy subjects (30 male, 37 female) ages 20–93. No significant differences in total or M-MDSC levels were detected for ages ≤60 compared to > 60 (p = 0.5 and p = 0.8, respectively). Finally, assay results demonstrated significantly higher MDSC levels among patients with hepatocellular carcinoma (N = 55) compared to age-matched healthy controls (N = 27) for total and M-MDSC (p = 0.006 and 0.004, respectively). CONCLUSIONS: MDSC are a heterogenous group of cells, and their quantitation in WB can be affected by a number of pre-analytical variables. Consideration of these factors, and measurement using a material type that has not been manipulated, such as whole blood, is likely to yield the most accurate results. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-019-0674-1) contains supplementary material, which is available to authorized users. BioMed Central 2019-08-28 /pmc/articles/PMC6714080/ /pubmed/31462270 http://dx.doi.org/10.1186/s40425-019-0674-1 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Apodaca, Minjun C.
Wright, Amy E.
Riggins, Angela M.
Harris, William P.
Yeung, Raymond S.
Yu, Lei
Morishima, Chihiro
Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title_full Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title_fullStr Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title_full_unstemmed Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title_short Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
title_sort characterization of a whole blood assay for quantifying myeloid-derived suppressor cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714080/
https://www.ncbi.nlm.nih.gov/pubmed/31462270
http://dx.doi.org/10.1186/s40425-019-0674-1
work_keys_str_mv AT apodacaminjunc characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT wrightamye characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT rigginsangelam characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT harriswilliamp characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT yeungraymonds characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT yulei characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells
AT morishimachihiro characterizationofawholebloodassayforquantifyingmyeloidderivedsuppressorcells